Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Cordarone MedGuide To Be Co-Packaged

This article was originally published in The Pink Sheet Daily

Executive Summary

Pharmacists are being given 100 medication guides to distribute with the anti-arrhythmic as Wyeth develops new packaging.

You may also be interested in...



Rythmol SR Warning Letter Cites Lack Of "Any" Risk Information

Promotional pieces aimed at encouraging pharmacy stocking expand the antiarrhythmic's indication and obscure its risks, FDA's ad division says.

Rythmol SR Warning Letter Cites Lack Of "Any" Risk Information

Promotional pieces aimed at encouraging pharmacy stocking expand the antiarrhythmic's indication and obscure its risks, FDA's ad division says.

Wyeth's Cordarone Adds Patient "MedGuide"

The anti-arrhythmic will be dispensed with a patient medication guide highlighting the risk of pulmonary toxicity, liver injury and exacerbation of arrhythmias. Copies of the MedGuide will be included in shipments of the drug for distribution by pharmacists.

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel